Sotac Pharmaceuticals

Sotac Pharmaceuticals Net Debt per Share

The Net Debt per Share of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 25, 2026 is 37.51 INR. In the previous year, Net Debt per Share was 19.46 INR — a change of 92.76% (higher).

Net Debt per Share

37.51INR

YoY

92.76%

Last updated:

Net Debt per Share of Sotac Pharmaceuticals is 2025 37.51 INR. Net Debt per Share of Sotac Pharmaceuticals was 2024 19.46 INR. It decreases by 92.76% higher compared to the previous year.

The Sotac Pharmaceuticals Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2020
11.64 INR
Jan 1, 2021
15.10 INR
Jan 1, 2022
6.66 INR
Jan 1, 2024
19.46 INR
Jan 1, 2025
37.51 INR
The Sotac Pharmaceuticals Net Debt per Share history
YEARNet Debt per ShareYoY
37.51INR+92.76%
19.46INR+192.12%
6.66INR-55.90%
15.10INR+29.80%
11.64INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Net Debt per Share of Sotac Pharmaceuticals is 37.51 INR in 2025.

Net Debt per Share of Sotac Pharmaceuticals changed from 19.46 INR to 37.51 INR, representing a 92.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals